Updated:
CutisPharma
CutisPharma is a pharmaceutical compounding company based in Wilmington, United States, established in 1998. It has secured $20 million in total funding.
CutisPharma
CutisPharma is a pharmaceutical compounding company based in Wilmington, United States, established in 1998. It has secured $20 million in total funding.
General information
Firm type
Specialty pharmaceuticals (compounding kits)
Year founded
1998
Location
Region
North America
Country
United States
City
Wilmington
Corporate office
Wilmington, United States
Sector focus
Frequently asked questions
What does CutisPharma do?
CutisPharma develops and markets prescription topical medications for dermatological conditions. Its focus includes compounded preparations and FDA-approved alternatives targeting skin disorders such as psoriasis and eczema (per public record).
Is CutisPharma structured as a family office or an asset manager?
Public records do not indicate that CutisPharma operates as a family office or asset manager. It appears to be a privately held operating company in the pharmaceutical sector, with no disclosed investment vehicles or external capital management.
Who owns CutisPharma?
Ownership of CutisPharma is not publicly documented. The firm may be privately held by individuals or a family, but no principals or wealth sources are disclosed in available sources.
What products does CutisPharma offer?
CutisPharma's product portfolio includes topical pharmaceuticals for dermatological conditions, with an emphasis on compounded preparations. Specific product names are not widely publicized, but the firm operates in the regulatory framework of the US FDA (per public record).
Does CutisPharma have any publicly reported investment activity?
No publicly reported investment activity, AUM, or deployment figures exist for CutisPharma. The firm does not appear to participate in external fund commitments, direct co-investments, or capital-raising activities typical of family offices or asset managers.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on investors?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: